Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab. Diotti R A, Capra R, Moiola L, Caputo V, De Rossi N, Sangalli F, Martinelli V, Burioni R, Clementi M, Mancini N Viruses. 2016; 8(5). PMID: 27164128. Abstract CommentRecommendBookmarkWatch
